Dermatologic Disease
Conditions
Keywords
PSO, PSA, SLE, PBMC
Brief summary
Part of psoriasis and psoriatic arthritis patients treated with biologics and met primary failure. Therefore, we are going to create a cell based platform to evaluate the treatment effects of different biologics on psoriasis and psoriatic arthritis patients before prescribed by physicians
Detailed description
PBMCs isolated from psoriasis and psoriatic arthritis and incubated with Group A streptococcus and different biologics for 24 hours. Cytokines expression in the culture supernatants will be measured and the data can be reference for physician's prescription.
Interventions
DIAGNOSTIC_TESTMarkers data from PBMCs
Prescreen markers from patient individual PBMCs treating with streptococcus and different biologics.
Sponsors
Taichung Veterans General Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
* 1\. Healthy control without underline disease such as psoriasis and psoriatic arthritis. 2. Psoriasis been diagnosed for over six months and PASI \>10. 3.Psoriatic arthritis been diagnosed for over six months and \>1 swallow and tender joints
Exclusion criteria
* nil
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PASI score | 2 weeks to 3 months | Psoriasis skin condition and severity |
| swelling joint count and tenderness joint count | 2 weeks to 3 months | PSA severity |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| CRP | 3-6 months | blood test |
| DLQI | 6 months | paper to investigate patient life quality |
Contacts
Primary ContactChung-Yang Yen, MDPhD
Outcome results
None listed